Comparative Pharmacology
Head-to-head clinical analysis: NICORETTE versus NICORETTE MINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NICORETTE versus NICORETTE MINT.
NICORETTE vs NICORETTE (MINT)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine binds to nicotinic acetylcholine receptors (nAChRs) in the brain, stimulating dopamine release in the mesolimbic pathway, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.
For smoking cessation, apply one 2 mg or 4 mg lozenge (mint) every 1-2 hours as needed for cravings, up to 15 lozenges per day. Use 4 mg lozenge if first cigarette is within 30 minutes of waking. Do not chew; allow to dissolve slowly (20-30 minutes). Frequency should be tapered after 6 weeks.
None Documented
None Documented
The terminal elimination half-life of nicotine is approximately 2 hours. This short half-life necessitates frequent dosing or continuous delivery to maintain therapeutic levels. Cotinine, the major metabolite, has a half-life of 15-20 hours.
2 hours (range 1-4) for nicotine; terminal half-life 10-12 hours for cotinine; clinical context: short t½ requires frequent dosing. Half-life prolonged in hepatic impairment.
Nicotine is extensively metabolized in the liver, primarily to cotinine. Renal excretion accounts for 2-35% of nicotine elimination unchanged, depending on urine pH (acidic urine increases excretion). Biliary/fecal excretion is minimal (<5%). Total clearance is about 1 L/min, with renal clearance of about 100 mL/min.
Renal: 60-80% as metabolites (cotinine, nicotine N-oxide), 10-20% unchanged; biliary/fecal: <10%
Category C
Category C
Smoking cessation aid
Smoking cessation aid